The current view on biological potency of cationically modified chitosan

Journal of Physiology and Pharmacology

Volumn 65, Issue 3, 2014, Pages 341-347

  Stefan, J ^a   Lorkowska Zawicka, B ^a   Kaminski, K ^b   Szczubialka, K ^b   Nowakowska, M ^b   Korbut, R ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Apoe knockout mouse; Atherosclerosis; Cationically modified chitosan; Chitosan; Heparin; Hypercholesterolemia; Lipid metabolism; Platelet aggregation; Quaternization; Red blood cells deformability

Indexed keywords

APOLIPOPROTEIN; CHITOSAN; FLUORESCEIN ISOTHIOCYANATE; HEPARIN; HEPARIN ANTAGONIST; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; N (2 HYDROXYPROPYL) 3 TRIMETHYLAMMONIUM CHITOSAN CHLORIDE; THROMBOXANE A2; UNCLASSIFIED DRUG; N-(2-HYDROXYPROPYL)-3-TRIMETHYLAMMONIUM CHITOSAN; QUATERNARY AMMONIUM DERIVATIVE;

ATHEROSCLEROSIS; BIOCOMPATIBILITY; BIODEGRADABILITY; BIOLOGICAL ACTIVITY; CHOLESTEROL BLOOD LEVEL; DOWN REGULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG POTENCY; ERYTHROCYTE DEFORMABILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID METABOLISM; MEAN CORPUSCULAR VOLUME; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIMULATION; THROMBOCYTE AGGREGATION; WOUND HEALING; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY;

ANIMALS; CHITOSAN; HUMANS; QUATERNARY AMMONIUM COMPOUNDS;

EID: 84902472650     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Samal SK, Dash M, Van Vlierberghe S, et al. Cationic polymers and their therapeutic potential. Chem Soc Rev 2012; 41: 7147-7194.
2. Lai WF. In vivo nucleic acid delivery with PEI and its derivatives: current status and perspectives. Expert Rev Med Devices 2011; 8: 173-185.
3. Hamano Y. Occurrence, biosynthesis, biodegradation, and industrial and medical applications of a naturally occurring e-poly-L-lysine. Biosci Biotechnol Biochem 2011; 75: 1226-1233.
4. Song W, Tang Z, Li M, et al. Tunable pH-sensitive poly(b-amino ester)s synthesized from primary amines and diacrylates for intracellular drug delivery. Macromol Biosci 2012; 12: 1375-1383.
5. Shen Y, Tang H, Zhan Y, Van Kirk EA, Murdoch WJ. Degradable poly(b-amino ester) nanoparticles for cancer cytoplasmic drug delivery. Nanomedicine 2009; 5: 192-201.
6. Agarwal S, Zhang Y, Maji S, Greiner A. PDMAEMA based gene delivery materials. Materials Today 2012; 15: 388-393.
7. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev 2009; 109: 259-302.
8. Itaka K, Ishii T, Hasegawa Y, Kataoka K. Biodegradable polyamino acid-based polycations as safe and effective gene carrier minimizing cumulative toxicity. Biomaterials 2010; 31: 3707-3714.
9. Moreau E, Domurado M, Chapon P, Vert M, Domurado D. Biocompatibility of polycations: in vitro agglutination and lysis of red blood cells and in vivo toxicity. J Drug Target 2002; 10: 161-173.
10. Riva R, Ragelle H, Des Rieux A, Duhem N, Jerome C, Preat V. Chitosan and chitosan derivatives in drug delivery and tissue engineering. Adv Polymer Sci 2011; 244: 19-44.
11. Ruiz-Herrera J. Fungal Cell Walls: Structure, Synthesis, and Assembly. Boca Raton, CRC Press, 1992.
12. Khor E. Chitin: Fulfilling a Biomaterials Promise. Oxford, Elsevier Science and Technology, 2001.
13. Xia W, Liu P, Zhang J, Chen J. Biological activities of chitosan and chitooligosaccharides. J Food Hydrocoll 2011; 25: 170-179.
14. Knorr D. Use of chitinous polymers in food - a challenge for food research and development. Food Technol 1984; 38: 85-97.
15. Kim S, Rajapakse N. Enzymatic production and biological activities of chitosan oligosaccharides (COS): a review. Carbohydr Polym 2005; 62: 357-368.
16. Majeti NV, Kumar R. A review of chitin and chitosan. React Funct Polym 2000; 46: 1-27.
17. Shahidi F, Synowiecki J. Isolation and characterization of nutrients and value-added product from snow crab (Chinoecetes opilio) and shrimp (Pandalus borealis) processing discards. J Agric Food Chem 1991; 39: 1527-1532.
18. Yamada A, Shibbuya N, Komada O, Akatsuka T. Induction of phytoalexin formation in suspension-cultured rice cells by N-acetylchitooligosaccharides. Biosci Biotechnol Biochem 1993; 57: 405-409.
19. Peniche-Covas C, Alwarez LW, Arguelles-Monal W. The adsorption of mercuric ions by chitosan. J Appl Polym Sci 1987; 46: 1147-1150.
20. Jeuniaux C. Chitosan as a tool for the purification of waters. In: Chitin in Nature and Technology. RA Muzzarelli, C Jeuniaux, GW Gooday (eds.). New York, Plenum Press 1986, 551-570.
21. Zeng L, Qin C, Wang W, Chi W, Li W. Absorption and distribution of chitosan in mice after oral administration. Carbohydr Polym 2008; 71: 435-340.
22. Chae S Y, Jang M, Nah J. Influence of molecular weight on oral absorption of water soluble chitosans. J Control Release 2005; 102: 383-394.
23. Ventura P. Lipid lowering activity of chitosan, a new dietary integrator. Chitin Enzymol 1996; 2: 55-62.
24. Bokura H, Kobayashi S. Chitosan decreases total cholesterol in women: a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr 2003; 57: 721-725.
25. Maezaki Y, Tsuji K, Nakagawa Y, et al. Hypocholesterolemic effect of chitosan in adult males. Biosci Biotechnol Biochem 1993; 57: 1439-1444.
26. Ormrod DJ, Holmes CC, Miller TE. Dietary chitosan inhibits hypercholesterolaemia and atherogenesis in the apolipoprotein E-deficient mouse model of atherosclerosis. Atherosclerosis 1998; 138: 329-334.
27. Allan CR, Hadwiger LA. The fungicidal effect of chitosan on fungi of varying cell wall composition. Exp Mycol 1979; 3: 285-287.
28. Vinsova J, Vavrikova E. Recent advances in drugs and prodrugs design of chitosan. Curr Pharm Des 2008; 14: 1311-1326.
29. Qin CQ, Li HR, Xiao Q, Liu Y, Zhu JC, Du YM. Water-solubility of chitosan and its antimicrobial activity. Carbohydr Polym 2006; 63: 367-374.
30. Bernkop-Schnurch A, Dunnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm 2012; 81: 463-9.
31. Sumit S, Shikha L, Murthy RS. Potential of chitosan for nose to brain drug delivery. Int J Pharm Sci Rev Res 2012; 16: 47-55.
32. Mukhopadhyay P, Mishra R, Rana D, Kundu PP. Strategies for effective oral insulin delivery with modified chitosan nanoparticles: a review. Prog Polym Sci 2012; 37: 1457-1475.
33. Sezer AD, Cevher E. Topical drug delivery using chitosan nano- and microparticles. Expert Opin Drug Deliv 2012; 9: 1129-1146.
34. Garcia-Fuentes M, Alonso MJ. Chitosan-based drug nanocarriers: where do we stand? J Control Release 2012; 161: 496-504.
35. Grenha A. Chitosan nanoparticles: a survey of preparation methods. J Drug Target 2012; 20: 291-300.
36. Mengatto LN, Helbling IM, Luna JA. Recent advances in chitosan films for controlled release of drugs. Recent Pat Drug Deliv Formul 2012; 6: 156-170.
37. Sandri G, Rossi S, Bonferoni MC, Ferrari F, Mori M, Caramella C. The role of chitosan as a mucoadhesive agent in mucosal drug delivery. J Drug Deliv Sci Technol 2012; 22: 275-284.
38. Basaran E, Yazan Y. Ocular application of chitosan. Expert Opin Drug Deliv 2012; 9: 701-712.
39. Gulbake A, Jain SK. Chitosan: a potential polymer for colon-specific drug delivery system. Expert Opin Drug Deliv 2012; 9: 713-729.
40. Pahwa R, Saini N, Kumar V, Kohli K. Chitosan-based gastroretentive floating drug delivery technology: an updated review. Expert Opin Drug Deliv 2012; 9: 525-539.
41. Ramesan RM, Sharma CP. Modification of chitosan nanoparticles for improved gene delivery. Nanomedicine (Lond) 2012; 7: 5-8.
42. Al-Qadi S, Grenha A, Remunan-Lopez C. Chitosan and its derivatives as nanocarriers for siRNA delivery. J Drug Deliv Sci Technol 2012; 22: 29-42.
43. Jeon YJ, Kim SK. Antitumor activity of chitosan oligosaccharides produced in ultrafiltration membrane reaction system. J Microbiol Biotechnol 2002; 12: 503-507.
44. Peluso G, Petillo O, Ranieri M, et al. Chitosan-mediated stimulation of macrophage function. Biomaterials 1994; 15: 1215-1220.
45. Senel S, McClure SJ. Potential applications of chitosan in veterinary medicine. Adv Drug Deliv Rev 2004; 56: 1467-1480.
46. Rodriguez-Merchan EC. Local fibrin glue and chitosan-based dressings in haemophilia surgery. Blood Coagul Fibrinolysis 2012; 23: 473-476.
47. Liu SH, He S P, Chiang MT. Effects of long-term feeding of chitosan on postprandial lipid responses and lipid metabolism in a high-sucrose-diet-impaired glucose-tolerant rat model. J Agric Food Chem 2012; 60: 4306-4313.
48. Hayashi K, Ito M. Antidiabetic action of low molecular weight chitosan in genetically obese diabetic KK-A y mice. Biol Pharm Bull 2002; 25: 188-192.
49. Xu C, Lei C, Meng L, Wang C, Song Y. Chitosan as a barrier membrane material in periodontal tissue regeneration. J Biomed Mater Res B Appl Biomater 2012; 100: 1435-1443.
50. Muzzarelli RA, Greco F, Busilacchi A, Sollazzo V, Gigante A. Chitosan, hyaluronan and chondroitin sulfate in tissue engineering for cartilage regeneration: a review. Carbohydr Polym 2012; 89: 723-739.
51. Gao W, Lai JC, Leung SW. Functional enhancement of chitosan and nanoparticles in cell culture, tissue engineering, and pharmaceutical applications. Front Physiol 2012; 3: 321.
52. Grolik M, Szczubialka K, Wowra B, et al. Hydrogel membranes based on genipin-cross-linked chitosan blends for corneal epithelium tissue engineering. J Mater Sci Mater Med 2012; 23: 1991-2000.
53. Ueno H, Mori T, Fujinaga T. Topical formulations and wound healing applications of chitosan. Adv Drug Deliv Rev 2001; 52: 105-115.
54. Bacon A, Makin J, Chatfield N. A novel mucosal influenza vaccine. Res Immunol 1998; 149: 98.
55. McNeela EA, O'Connor D, Jabbal-Gill I, et al. A mucosal vaccine against diptheria: formulation of cross reacting material (CRM 197) of diptheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vacccine 2001; 19: 1198-1199.
56. Le Buanec H, Vetu C, Lachgar A, et al. Induction in mice of anti-Tat mucosal immunity by the intranasal and oral routes. Biomed Pharmacother 2001; 55: 316-320.
57. Westerink MA, Smithson SL, Srivastava N, Blonder J, Coeshott C, Rosenthal GJ. ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine 2002; 20: 711-723.
58. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine peanut allergy model. Nat Med 1999; 5: 387-391.
59. Kosaka T, Kaneko Y, Nakada Y, Matsuura M, Tanaka S. Effect of chitosan implantation on activation of canine macrophages and polymorphonuclear cells after surgical stress. J Vet Med Sci 1996; 58: 963-967.
60. Lim SH, Hudson SM. Synthesis and antimicrobial activity of a water-soluble chitosan derivative with a fiber-reactive group. Carbohydr Res 2004; 339: 313-319.
61. Guo Z, Xing R, Liu S, Zhong Z, Ji X, Wang L, Li P. The influence of the cationic of quaternized chitosan on antifungal activity. Int J Food Microbiol 2007; 118: 214-217.
62. Sandri G, Rossi S, Bonferoni MC, et al. Buccal penetration enhancement properties of N-trimethyl chitosan: influence of quaternization degree on absorption of a high molecular weight molecule. Int J Pharm 2005; 297: 146-155.
63. Kotze AF, Luessen HL, de Leeuw BJ, Boer B G, Verhoef JC, Junginger HE. N-trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: in vitro evaluation in intestinal epithelial cells (Caco-2). Pharm Res 1997; 14: 1197-1202.
64. Wu J, Wei W, Wang LY, Su ZG, Ma GH. A thermosensitive hydrogel based on quaternized chitosan and poly(ethylene glycol) for nasal drug delivery system. Biomaterials 2007; 28: 2220-2232.
65. Ji QX, Zhong DY, Lu R, Zhang WQ, Deng J, Chen XG. In vitro evaluation of the biomedical properties of chitosan and quaternized chitosan for dental applications. Carbohydr Res 2009; 344: 1297-1302.
66. Toshkova R, Manolova N, Gardeva E, et al. Antitumor activity of quaternized chitosan-based electrospun implants against graffi myeloid tumor. Int J Pharm 2010; 400: 221-233.
67. Kaminski K, Szczubialka K, Zazakowny K, Lach R, Nowakowska M. Chitosan derivatives as novel potential heparin reversal agents. J Med Chem 2010; 53: 4141-4147.
68. Kaminski K, Zazakowny K, Szczubialka K, Nowakowska M. pH-sensitive genipin-cross-linked chitosan microspheres for heparin removal. Biomacromolecules 2008; 9: 3127-3132.
69. Chou TC, Fu E, Wu CJ, Yeh JH. Chitosan enhances platelet adhesion and aggregation. Biochem Biophys Res Commun 2003; 302: 480-483.
70. Rao SB, Sharma CP. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J Biomed Mater Res 1997; 34: 21-28.
71. Okamoto Y, Shibazaki K, Minami S, Matsuhashi A, Tanioka S, Shigemasa Y. Evaluation of chitin and chitosan on open wound healing in dogs. J Ve t Med Sci 1995; 57: 851-854.
72. Ueno H, Yamada H, Tanaka I, et al. Accelerating effects of chitosan for healing and early phase of experimental open wound in dogs. Biomaterials 1999; 20: 1407-1414.
73. Brandenberg G, Leibrock LG, Shuman R, Malette WG, Quigley H. Chitosan: a new topical hemostatic agent for diffuse capillary bleeding in brain tissue. Neurosurgery 1984; 15: 9-13.
74. Klokkevold PR, Fukayama H, Sung EC, Bertolami CN. The effect of chitosan (poly-N-acetyl glucosamine) on lingual hemostasis in heparinized rabbits. J Oral Maxillofac Surg 1999; 57: 49-52.
75. Chmiel B, Grabowska-Bochenek R, Piskorska D, Cierpka L. Diet-induced hypercholesterolaemia causes increase of red blood cell deformability in rabbits. Chirurg Pol 2002; 4: 107-112.
76. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-471.
77. Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353.
78. Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004; 55: 503-517.
79. Smith DD, Tan X, Tawfik O, Milne G, Stechschulte DJ, Dileepan KN. Increased aortic atherosclerotic in female apolipoprotein E-null mice is associated with elevated thromboxane A2 and decreased prostacyclin production. J Physiol Pharmacol 2010; 61: 309-316.
80. Jawien J, Korbut R. The current view on the role of leukotrienes in atherogenesis. J Physiol Pharmacol 2010; 61: 647-650.
81. Toton-Zuranska J, Gajda M, Pyka-Fosciak G, et al. AV E 0991 - angiotensin-(1-7) receptor agonist, inhibits atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2010; 61: 181-183.
82. Pawlowska M, Gajda M, Pyka-Fosciak G, et al. The effect of doxycycline on atherogenesis in ApoE-knockout mice. J Physiol Pharmacol 2011; 62: 247-250.
83. Ngo DN, Qian ZJ, Je JY, Kim MM, Kim SK. Aminoethyl chitooligosaccharides inhibit the activity of angiotensin converting enzyme. Process Biochem 2008; 43: 119-123.
84. Parra-Barraza H, Burboa MG, Sanchez-Vazquez M, Juarez J, Goycoolea FM, Valdez MA. Chitosan-cholesterol and chitosan-stearic acid interactions at the air-water interface. Biomacromolecules 2005; 6: 2416-2426.
85. Xu G, Huang X, Qiu L, Wu J, Hu Y. Mechanism study of chitosan on lipid metabolism in hyperlipidemic rats. Asia Pac J Clin Nutr 2007; 16 (Suppl 1): 313-317.